| Identification | Back Directory | [Name]
Chemerin-9 (149-157) | [CAS]
676367-27-4 | [Synonyms]
Chemerin-9
Chemerin-9 (149-157)
L-Serine, L-tyrosyl-L-phenylalanyl-L-prolylglycyl-L-glutaminyl-L-phenylalanyl-L-alanyl-L-phenylalanyl- | [Molecular Formula]
C54H66N10O13 | [MDL Number]
MFCD32068013 | [MOL File]
676367-27-4.mol | [Molecular Weight]
1063.16 |
| Hazard Information | Back Directory | [Description]
Chemerin-9 (149-157), the nonapeptide (149)YFPGQFAFS(157) (chemerin-9), corresponding to the C terminus of processed chemerin, retains most of the activity of the full-size protein, with regard to agonism toward the chemerinR[1].
| [Uses]
Chemerin-9 (149-157) is a potent agonist of chemokine-like receptor 1 (CMKLR1) . Chemerin-9 (149-157) has anti-inflammatory activity. Chemerin-9 (149-157) stimulates phosphorylation of Akt and ERK as well as ROS production. Chemerin-9 (149-157) ameliorates Aβ1-42-induced memory impairmen. Chemerin-9 (149-157) regulates immune responses, adipocyte differentiation, and glucose metabolism[1][2][3][4]. | [in vivo]
Chemerin-9 (149-157) (0.2 mg/kg; i.p.; daily, for 42 days) alleviates glucose intolerance and IR in PDM mice[1].
Chemerin-9 (149-157) (7.7? μg /kg; i.h.; daily, for 28 days) has anti-inflammatory and anti-angiogenic effects in ApoE-/- mice and protects the abdominal aorta from MMP damage[2].
Chemerin-9 (149-157) (8 μg/kg; ICV; daily; for 14 d; male Kunming mice) ameliorates Aβ1-42-induced memory impairment[3]. | Animal Model: | PDM mice[1] | | Dosage: | 0.2 mg/kg | | Administration: | Intraperitoneal injection; daily, for 42 days | | Result: | Increased expression of chemerin, GLUT2, and PDX1, which led to the alleviation of glucose intolerance and IR in PDM model mice. |
| Animal Model: | ApoE-/- mice[2] | | Dosage: | 7.7 μg /kg | | Administration: | Subcutaneous injection; daily, for 28 days | | Result: | Suppressed the enlargement of abdominal aorta and reversed the SMC loss. |
| Animal Model: | ApoE-/- mice[2] | | Dosage: | 7.7 μg /kg | | Administration: | Subcutaneous injection; daily, for 28 days | | Result: | Down-regulated MMP2 and MMP-9 expression and decreased the levels of chemerin and CMKLR1. |
| Animal Model: | Male Kunming mice[3] | | Dosage: | 8 μg/kg | | Administration: | Intracerebroventrical injection; daily; for 14 days | | Result: | Increased in the levels of pro-in?ammatory cytokines such as interleukin-1β (IL-1β), tumor necrosis factor (TNF-α) and interleukin-6 (IL-6) in the hippocampus. |
| [storage]
Store at -20°C | [References]
[1]. Wittamer V, et al. The C-terminal nonapeptide of mature chemerin activates the chemerin receptor with low nanomolar potency. J Biol Chem. 2004 Mar 12;279(11):9956-62. |
|
| Company Name: |
Ontores Biotech
|
| Tel: |
0571-88760729 18072970094 |
| Website: |
www.ontoresinc.cn |
|